Tech Company Financing Transactions
DecImmune Therapeutics Funding Round
On 9/27/2010, DecImmune Therapeutics secured $1 million in financing from Amgen Ventures, Astellas Venture Capital and HealthCare Ventures.
Transaction Overview
Company Name
Announced On
9/27/2010
Transaction Type
Venture Equity
Amount
$1,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The new funds will enable accelerated development of the company's proprietary technology to reduce tissue damage, accelerate healing, and improve outcomes associated with ischemia reperfusion injury.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
47 Thorndike St.
Boston, MA 02141
USA
Boston, MA 02141
USA
Phone
Website
Email Address
Overview
DecImmune Therapeutics is a Boston-based biotech company developing drugs for inflammation and autoimmunity.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Scientific Officer
Walter Newman
Co-Founder
Michael Carroll
Co-Founder
Francis Moore
President
Christopher Mirabelli
Browse more venture capital transactions:
Prev: 9/27/2010: OnePIN venture capital transaction
Next: 9/27/2010: Quantenna Communications venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs